John A. Roberts, MBA
Chief Executive Officer and President
Mr. Roberts brings deep operational and financial experience to CGI with a strong track record of disciplined growth, operational excellence, and shareholder value creation in multiple public and private healthcare technology and service companies including InfoLogix, AdvantEdge Healthcare Solutions, Clarient and, most recently, VirMedica. His professional background includes a deep understanding of clinical and healthcare billing, diagnostics, clinical operations, and healthcare-focused IT. In addition, Mr. Roberts is a long-standing board member and incoming President-elect of the Drug Information Association (DIA), a neutral, global nonprofit association focused on advancing health care product development around the world by connecting stakeholders to interdisciplinary insights and innovation.
Mr. Roberts has a Master of Business Administration and Bachelor of Science from the University of Maine. He has served as a recognized thought leader and expert panelist for numerous publications and programs related to corporate finance and mergers and acquisitions in the healthcare industry.
Ralf Brandt, PhD
President, Discovery and Early Development
Dr. Brandt is the co-founder of vivoPharm | A CGI Company. He is a biochemist and cell biologist with over 15 years experience in research programs of experimental oncology. Furthermore, he has immense experience in in vivo pharmacology and anti-cancer drug profiling. He received his Licence (BSc in Biochemistry and Animal Physiology) in 1986, and his PhD (in Biochemistry) in 1991 from the Martin-Luther University of Halle-Wittenberg, Germany. Dr. Brandt was employed at research positions at the National Cancer Institute in Bethesda, MD, USA and at Schering AG, Germany. Since 1990, Dr. Brandt has been active in the field of preclinical oncology. He led the Tumour Biology program at Novartis Pharma AG, Switzerland and established several transgenic mouse lines developing tumours under the control of oncogenes. During Dr. Brandt’s long career in the pharmaceutical industry he has acquired significant knowledge and expertise in leading business units and representation of services to the pre-clinical research market. Dr. Brandt is a member of the Scientific Advisory Board at Receptor Inc. in Toronto Canada and Propanc in Melbourne VIC, Australia.
Michael McCartney, MBA
Chief Commercial Officer
Mr. McCartney has more than 20 years of life sciences, diagnostic and lab services industry experience with senior level responsibilities in sales management, global marketing and business development. Prior to joining Cancer Genetics, Mr. McCartney served as the Chief Executive Officer at SciKon Innovation, Inc., an early-stage life science company, where he was responsible for guiding the company through fundraising activities as well as developing and executing an exit strategy for the company. Prior to his appointment as CEO, Michael served as Chief Operating Officer at SciKon, where he was responsible for developing the sales and marketing organizations, creating the overall sales process, strategic direction, as well as company and individual goals. Early in his career, Mr. McCartney held positions across multiple disciplines at BioAgilytix Labs, Roche, Siemens and Abbott.
Mr. McCartney holds a Master of Business Administration degree from LaSalle University in Philadelphia and a Bachelor's degree in Business Administration with an emphasis on finance from Indiana University of Pennsylvania.
Chief Financial Officer
Prior to his appointment as Chief Financial Officer, Mr. Miles served the Company as a financial and accounting consultant since July 2018. Prior to joining the Company, Mr. Miles served as President and CFO of Catalytic Consulting LLC, a management advisory firm specializing in finance, accounting and operations, since 2015. From 2013 to 2015, Mr. Miles conducted research and engaged in thought leadership and panel discussions, focusing on finance in the healthcare and non-profit industries. From 2009 to 2013, Mr. Miles served as the Biopharma Controller for Developed Europe, Latin America and US Oncology at Pfizer. Prior to joining Pfizer, Mr. Miles served as Vice President - Global Expense Control and Analysis – Non-Personnel Expense at Lehman Brothers from 2006 to 2008. Prior to joining Lehman Brothers, Mr. Miles served in various finance and accounting roles with increasing responsibility at AT&T Mobility (formerly Cingular Wireless and BellSouth Mobility) from 1994 to 2006. Early in his career, Mr. Miles worked as an accountant at Grant Thornton (and a regional subscriber firm, Aldridge, Borden & Company, P.C.) from 1987 to 1994. Mr. Miles holds an MBA from Mercer University and a Bachelor of Science from the University of Alabama in Accounting. Mr. Miles is trained in Lean Six Sigma (Green Belt), is a CPA, and a member of FEI, AICPA, ACHE & HFMA.
Rob Fannon, MBA, MPH
Vice President of Biopharma Solutions
Rob Fannon brings more than 10 years of experience in operations, client management, molecular test and panel development, and biorepository management to CGI. Before joining CGI, Mr. Fannon served with Roche Molecular’s Biospecimen Management Division, where he oversaw biospecimen acquisition, panel production, project management, and client relations. Prior to his tenure at Roche, Fannon served as clinical operations manager at BioServe Biotechnologies, Ltd. In Beltsville, MD, where he was responsible for sales, business development, and client relations. From 2006 to 2010, Fannon served as an editor and analyst at Stansberry and Associates Investment Research, where he established an investment advisory publication focused on investment opportunities in publicly-traded biotech, life science, and healthcare companies. Fannon also spent two years as a business development associate at the Johns Hopkins Bloomberg School of Public Health, where he assessed intellectual property opportunities and sought licensing opportunities for research with provisional patent coverage. Mr. Fannon received his B.S. from East Carolina University and holds a Master of Public Health (MPH), and a Master of Business Administration (MBA) from Johns Hopkins University in Baltimore, MD.
Executive Vice President, Precision Medicine and Biopharma Solutions
Mr. Finger has more than 25 years of life sciences, diagnostic and lab services industry experience with senior level responsibilities focused on precision medicine, lab integrations and biomarker testing. Prior to joining Cancer Genetics, Mr. Finger served as Managing Director, Precision Medicine and Diagnostics for Kineticos, a life science consultancy providing actionable strategic guidance and tactical implementation to industry leaders within the Precision Medicine industry. Prior to that, Mr. Finger served for over 12 years with Laboratory Corporation of America. While at LabCorp, he held leadership positions in scientific affairs, preclinical services, bio-repository and operations. Early in his career, Mr. Finger worked for Wake Health Services and Duke University Medical Center.
Mr. Finger holds a Master’s Degree of Healthcare Administration from the University of North Carolina and a Bachelor’s Degree in Medical Technology from State University of New York.